©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2017; 9(8): 314-318
Published online Aug 15, 2017. doi: 10.4251/wjgo.v9.i8.314
Published online Aug 15, 2017. doi: 10.4251/wjgo.v9.i8.314
S-1 induced hepatic steatosis in patients with pancreatic cancer: Retrospective analysis
Kunihiro Tsuji, Hisashi Doyama, Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa 920-8530, Japan
Author contributions: Tsuji K designed this study and wrote the paper; Doyama H contributed to revision of the manuscript for important content.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Ishikawa Prefectural Central Hospital.
Informed consent statement: All study participants provided informed consent to study enrollment.
Conflict-of-interest statement: The authors declare that they have no financial considerations or relationships that may pose a conflict of interest.
Correspondence to: Dr. Kunihiro Tsuji, Department of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratsukihigashi, Kanazawa, Ishikawa 920-8530, Japan. m92162g@ipch.jp
Telephone: +81-76-2378211 Fax: +81-76-2385366
Received: December 13, 2016
Peer-review started: December 14, 2016
First decision: March 6, 2017
Revised: March 20, 2017
Accepted: June 12, 2017
Article in press: June 16, 2017
Published online: August 15, 2017
Processing time: 240 Days and 1.9 Hours
Peer-review started: December 14, 2016
First decision: March 6, 2017
Revised: March 20, 2017
Accepted: June 12, 2017
Article in press: June 16, 2017
Published online: August 15, 2017
Processing time: 240 Days and 1.9 Hours
Core Tip
Core tip: Drug induced hepatic steatosis is a rare form of liver injury. Although hepatic steatosis has been observed in some patients with pancreatic cancer who were administered S-1, the ability of 5-fluorouracil alone to induce hepatic steatosis has not been evaluated systematically. The purpose of our study was to determine whether S-1 induces hepatic steatosis in patients being treated for pancreatic cancer. After analyzing a total of 22 patients, we found that S-1 chemotherapy induced hepatic steatosis in some patients with pancreatic cancer within three months and the correlation between the development of hepatic steatosis and liver function was weak in these patients.